Edgewise Therapeutics, Inc. — Form D
Edgewise Therapeutics, Inc. of Boulder, CO, a company, filed a Form D exempt-offering notice with the SEC on 2020-12-10. The offering totals $95.0M, of which $95.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-12-10
- Form: D
- Accession: 0001710072-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $95.0M
- Amount sold: $95.0M
- Investors: 21
- Date of first sale: 2020-12-03
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-382855
Issuer
- Name: Edgewise Therapeutics, Inc.
- CIK: 0001710072
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 3415 Colorado Ave, Boulder, CO, 80303
- Phone: (303) 735-8373
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Kenneth Harrison | Director | Half Moon Bay, CA |
| KEVIN KOCH | Director | WOBURN, MA |
| Jonathan Root | Director | Aliso Viejo, CA |
| Alan Russell | Director | Boulder, CO |
| Peter Thompson | Director | Chanhassen, MN |
| KEVIN KOCH | Executive Officer | WOBURN, MA |
Other filings by this issuer (1)
More